Madrigal Pharmaceuticals (MDGL) Total Debt (2022 - 2025)
Historic Total Debt for Madrigal Pharmaceuticals (MDGL) over the last 10 years, with Q3 2025 value amounting to $339.8 million.
- Madrigal Pharmaceuticals' Total Debt rose 19017.14% to $339.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $339.8 million, marking a year-over-year increase of 19017.14%. This contributed to the annual value of $117.6 million for FY2024, which is 180.9% up from last year.
- As of Q3 2025, Madrigal Pharmaceuticals' Total Debt stood at $339.8 million, which was up 19017.14% from $118.4 million recorded in Q2 2025.
- Over the past 5 years, Madrigal Pharmaceuticals' Total Debt peaked at $339.8 million during Q3 2025, and registered a low of $48.7 million during Q2 2022.
- Over the past 4 years, Madrigal Pharmaceuticals' median Total Debt value was $115.8 million (recorded in 2023), while the average stood at $114.6 million.
- Over the last 5 years, Madrigal Pharmaceuticals' Total Debt had its largest YoY gain of 19017.14% in 2025, and its largest YoY loss of 151.71% in 2025.
- Madrigal Pharmaceuticals' Total Debt (Quarter) stood at $49.3 million in 2022, then skyrocketed by 134.29% to $115.5 million in 2023, then rose by 1.81% to $117.6 million in 2024, then surged by 188.98% to $339.8 million in 2025.
- Its Total Debt was $339.8 million in Q3 2025, compared to $118.4 million in Q2 2025 and $118.0 million in Q1 2025.